Pipeline/Technology

Epigene Therapeutics is advancing

Description Lead Generation Lead Optimization Preclinical FIH/Phase 1/2 Pivotal Trials
NEO2734
DUAL BET & CBP/P300 INHIBITOR
NEO1132
DUAL BET & CBP/P300 INHIBITOR
CBP/P300
INHIBITOR

 

  • NEO2734, a novel orally-bioavailable dual BET & CBP/300 inhibitor
  • NEO1132, a novel dual BET & CBP/P300 inhibitor
  • CBP/P300 inhibitor lead generation program

Dual BET and CBP/P300 inhibition

  • A BET inhibitor blocks the BRD family members from binding histones and activating oncogenes
  • A CBP/P300 inhibitor blocks histone acetylation, thereby further prohibiting a range of BRD family members from binding histones and activating oncogenes

CBP/P300 inhibition

  • A CBP/P300 inhibitor blocks histone acetylation, thereby further prohibiting a range of BRD family members from binding histones and activating oncogenes

Companion biomarker program

  • Objective is to identify robust biomarkers to optimize patient selection
  • Predictive biomarkers such as: c-Myc, PI3K, MAP kinase, K-RAS, LKB1, MUC1 TRIM33, SMARCA4, SMARCA2, BROMO-10, SPOP mutations, EP300 and CBP mutations
  • Pharmacodynamic biomarkers including: HEXiM1, CCR1, CCR2, IL1RN, and CD180